Suraksha Diagnostic Limited — Investor Meet, 14-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Suraksha Diagnostic's H1 FY26 revenue hit 153.07 Cr (+17.8% YoY), with EBITDA at 49.62 Cr (32.8% margin). Q2 revenue grew 16.9% YoY, but EBITDA dipped to 24.97 Cr (31.7% margin) and PAT to 8.83 Cr. This was primarily due to heavy rains/floods (estimated 3-4 Cr revenue shortfall) and early festivities.

The company added 3 new centers in Q2, growing its network to 63, and launched Suraksha Genomics. Management aims for 15% FY26 revenue growth and 33-34% EBITDA margin, planning 12-15 new centers. While new centers (33% of network) currently impact overall margins, mature centers boast 37-38% EBITDA. The outlook for H2 is positive, with expected margin recovery as new centers scale. Management maintains a confident tone.